BioInvent International
LUND, SE / ACCESSWIRE / November 23, 2021 / BioInvent International (STO:BINV)
Friday, December 17 at 1 pm ET (7 pm CET)
BI-1206 is a Potential Treatment for non-Hodgkin's Lymphoma and Solid Tumors
BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that it will host a key opinion leader (KOL) webinar on BI-1206, a potential treatment for non-Hodgkin's lymphoma and solid tumors, on Friday, December 17, 2021 at 1:00pmET/7:00pmCET.
The webcast will feature KOL Michael Wang, M.D., from the MD Anderson Cancer Center, who will discuss the current treatment landscape and unmet medical need in treating patients with non-Hodgkin's lymphoma (NHL) and Mantle Cell Lymphoma (MCL).
BioInvent's management team will provide an update on the ongoing BI-1206 clinical studies for the treatment of non-Hodgkin's lymphoma and solid tumors, including an overview of the NHL data presented at ASH on December 11.
BI-1206 is BioInvent's lead drug candidate and is currently being investigated in two trials. One is evaluating the BI-1206 combination with rituximab for the treatment of non-Hodgkin's lymphoma; and the other evaluates BI-1206 in combination with anti-PD1 therapy Keytruda® (pembrolizumab) in solid tumors.
BI-1206 is a monoclonal antibody that selectivity binds to FcγRIIB (CD32B). By blocking FcγRIIB, BI-1206 can recover and enhance the activity of rituximab or other anti-CD20 monoclonal antibodies in the treatment of NHL. In addition, BI-1206 has the potential to reduce resistance to PD-1 immune checkpoint blockade, providing a new way to enhance anti-tumor immune responses in patients with solid tumors.
To register for the event, please click here.
Luhua (Michael) Wang, M.D. is a Professor in the department of Lymphoma & Myeloma at MD Anderson. Dr. Wang obtained his M.D. from Shandong Medical University and M.S. from Beijing University, Medical School. He completed his clinical training as a resident at Norwalk Hospital, Norwalk, Connecticut, and as a Fellow in Oncology and in Hematology at MD Anderson.
Dr. Wang has published more than 150 peer-reviewed papers and presented his work at meetings nationally and internationally. He is the current Director of Mantle Cell Lymphoma (MCL) Program of Excellence and Co-Director of Clinical Trials at MD Anderson.
During the past 15 years, he has focused on preclinical and clinical research and established an MCL-SCID-hu mouse model, which is the first human primary MCL animal model for the study of the biology and treatment of MCL. Dr. Wang has pioneered the work to improve the treatment of patients with MCL, including the introduction of BTK inhibitors such as ibrutinib and acalabrutinib in the treatment algorithm, and has performed extensive work with CAR-T cells for the treatment of these patients. His work has been published in the most prestigious medical journals such as the NEJM and the Lancet. He is currently the PI of the B-Cell Lymphoma Moon Shot Program at MD Anderson.
About BioInvent
BioInvent International AB (Nasdaq Stockholm:BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow on Twitter: @BioInvent.
For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations
+46 (0)46 286 85 50
cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.
Attachments
BioInvent Hosting Key Opinion Leader Webinar on BI-1206
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/674388/BioInvent-Hosting-Key-Opinion-Leader-Webinar-on-BI-1206
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Ascension Advisory Completes Industrial Sale Leaseback in Toledo, Spain on Behalf of OpenGate Capital17.12.2025 23:05:00 CET | Press release
TOLEDO, SPAIN / ACCESS Newswire / December 17, 2025 / Ascension Advisory is pleased to announce the successful closing of an industrial sale leaseback transaction in Toledo, Spain, completed on behalf of Aluminium Solutions Group (ASG), a portfolio company of OpenGate Capital. Aluminium Solutions Group is an industrial manufacturing business specializing in aluminium extrusion and value-added aluminium solutions, serving a range of industrial and commercial end markets across Europe. OpenGate Capital is a global private equity firm specializing in the acquisition and operation of businesses to create new value through operational improvements, innovation and growth. The transaction involved a 44,026 square meter industrial facility situated on a 56,330 square meter site, representing a mission-critical manufacturing asset for ASG's operations in Spain, Extrusiones de Toledo ("EXTOL"). As part of the sale leaseback, EXTOL executed a new long-term triple-net lease, allowing the company t
TruMerit and NAPNAP Team Up to Develop a Global Micro-credential for Pediatric Nursing Care17.12.2025 18:45:00 CET | Press release
PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / December 17, 2025 / TruMerit, a worldwide leader in international credentials evaluation to support health worker careers, and the National Association of Pediatric Nurse Practitioners (NAPNAP), The Leader in Pediatric Education for Nurse Practitioners®, have announced they will jointly develop a global micro-credential to help advance the knowledge and skills of the world's pediatric nursing workforce. The collaboration aims to improve health outcomes for infants, children, adolescents, and young adults worldwide amid a global shortage of pediatric nurses that is limiting access to evidence-based pediatric care in countries of all income levels. The partners envision that their micro-credential program will be the centerpiece of a larger initiative to engage global stakeholders in educating, assessing, and credentialing the nursing workforce in this specialization. A micro-credential is a short, competency-based recognition for specific s
SK tes Achieves NCSC CAS-S Accreditation for Comprehensive Onsite and Offsite Data Destruction and Sanitisation Services Across the UK17.12.2025 15:00:00 CET | Press release
LONDON, UK / ACCESS Newswire / December 17, 2025 / SK tes, a global leader in secure technology lifecycle management, is proud to announce that both its UK sites - Cannock, West Midlands and Irvine, Scotland - have achieved accreditation to the Sanitisation Assurance (CAS-S) Scheme by the UK's National Cyber Security Centre (NCSC) for its secure on-site shredding service. This dual-site accreditation enables SK tes to deliver secure data destruction and sanitisation services nationwide from these two strategic locations, to support clients across the whole of the UK. The CAS-S scheme certifies commercial IT asset sanitisation providers to rigorous government standards, ensuring central government (HMG) customers can easily access services that fully comply with NCSC requirements. With this accreditation, SK tes is authorised to provide: Mobile (offsite) destruction services up to SECRET: Devices are destroyed at the client's premises, ensuring sensitive information never leaves the org
AWM Wraps Up 2025 with Multiple Surf Venue Grand Openings16.12.2025 16:05:00 CET | Press release
Ending the Year on a High Note SOLANA BEACH, CA / ACCESS Newswire / December 16, 2025 / American Wave Machines, the surf technology company behind PerfectSwell® Surf Venues worldwide, concludes banner year with two grand openings and expansion into new markets. São Paulo Surf Club Key Year End Highlights: Riyue Bay: November 11 China Tourism Group celebrated the grand opening of PerfectSwell® Riyue Bay Surf Resort Zion: November 20 The Foundation Ceremony of PerfectSwell® Zion took place in Utah. São Paulo: November 29 JHSF celebrated the grand opening of São Paulo Surf Club "This year's results reflect a herculean effort from the team on improving efficiency, product delivery and commissioning. Finishing with two grand openings in one month is perhaps our most notable achievement. With PerfectSwell® Zion well underway and a third pool starting up in Brazil, 2026 will be just as memorable." - CEO Bruce McFarland "The wave quality achievements made this year have exceeded the expectatio
Eastman, AstraZeneca, Kraft Heinz, and P&G Recognized with OMP Supply Chain Awards16.12.2025 15:00:00 CET | Press release
MIAMI, FLORIDA / ACCESS Newswire / December 16, 2025 / AstraZeneca, Eastman, Kraft Heinz, and P&G have been recognized for their outstanding contribution at the recent OMP Conference. The four industry leaders were honored at the Miami event for their commitment to innovation and excellence, while driving real-world results across their global operations. The OMP Awards program turns the spotlight on organizations within the OMP Community that set new benchmarks in supply chain planning and inspire cross-industry progress and transformation. Eastman: Co-shaping Unison Planning™ in a long-term partnership A strategic OMP customer for nearly two decades, Eastman received the Long‑Term Partnership Award for co‑shaping the chemical industry solution of Unison Planning™. Eastman's vision and intense collaboration have helped redefine best practices in chemical supply chain planning and have been a positive influence on broader industry standards. Accepting the award, Baptiste Lebreton, Digi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom